Table 1.

Summary of CIDP variants and their treatment.

CIDP variant	Treatment	Prognosis	Special considerations
DADS-I	First-line IMT	Similar to CIDP	Need for hematological evaluation and monitoring
DADS MAG	Rituximab	Less favorable for DADS M	Rare worsening with rituximab reported
MADSAM	First-line IMT Consider 2nd line agents, rituximab, in refractory cases	Generally less favorable
Pure sensory	First-line IMT	Similar to CIDP	Responds well to IVIG or steroids
CISP	First-line IMT	Mostly similar to CIDP	Prone to relapse on tapering IMT
Pure motor	IVIG recommended as first line	Similar to CIDP	Steroid found to be equally efficacious but distinction from MMN needed
Focal variant	First-line IMT, may need maintenance therapy	Comparable to CIDP	Prone to relapse on tapering IMT
CIDP with IgG4 antibodies	Rituximab or cyclophosphamide (refractory to first-line IMT)	Poor compared to CIDP